Hologic, Inc. (HOLX) Reaches $45.76 After 8.00% Up Move, 4 Analysts Are Bullish Impax Laboratories (IPXL) Last Week

June 20, 2017 - By Peter Erickson

The stock of Hologic, Inc. (NASDAQ:HOLX) is a huge mover today! About 357,844 shares traded. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since June 20, 2016 and is uptrending. It has outperformed by 12.51% the S&P500.The move comes after 8 months positive chart setup for the $13.02B company. It was reported on Jun, 20 by Barchart.com. We have $49.42 PT which if reached, will make NASDAQ:HOLX worth $1.04 billion more.

Among 15 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Impax Laboratories Inc. had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was initiated by BMO Capital Markets with “Market Perform” on Wednesday, June 29. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Underperform” rating by Bank of America on Monday, November 7. The rating was initiated by Northland Capital with “Market Perform” on Tuesday, April 19. RBC Capital Markets maintained the shares of IPXL in report on Tuesday, February 23 with “Sector Perform” rating. The company was downgraded on Monday, November 14 by WallachBeth Capital. As per Wednesday, January 6, the company rating was initiated by JP Morgan. The stock of Impax Laboratories Inc (NASDAQ:IPXL) has “Market Perform” rating given on Tuesday, August 11 by Leerink Swann. The firm has “Neutral” rating given on Tuesday, September 27 by Goldman Sachs. On Monday, June 6 the stock rating was initiated by Goldman Sachs with “Sell”. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Hold” rating by Deutsche Bank on Wednesday, August 10. See Impax Laboratories Inc (NASDAQ:IPXL) latest ratings:

16/06/2017 Broker: Cantor Fitzgerald Rating: Overweight New Target: $20 Initiates Coverage On
28/12/2016 Broker: Janney Capital Rating: Neutral New Target: $15 Initiate

Since January 3, 2017, it had 0 insider purchases, and 19 insider sales for $8.60 million activity. $377,830 worth of Hologic, Inc. (NASDAQ:HOLX) was sold by ULLIAN ELAINE. Shares for $351,501 were sold by LEAMING NANCY. The insider CRAWFORD SALLY sold 17,396 shares worth $730,632. The insider Levy Lawrence M sold 9,837 shares worth $445,975. The insider Valenti Peter J. III sold $434,635.

Among 13 analysts covering Hologic (NASDAQ:HOLX), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Hologic had 22 analyst reports since July 24, 2015 according to SRatingsIntel. Bank of America downgraded the shares of HOLX in report on Wednesday, February 15 to “Neutral” rating. The rating was maintained by Jefferies with “Buy” on Friday, September 18. The firm has “Buy” rating by Jefferies given on Friday, May 26. The rating was maintained by Argus Research on Monday, August 3 with “Buy”. BTIG Research upgraded the shares of HOLX in report on Monday, October 26 to “Buy” rating. Stifel Nicolaus upgraded it to “Buy” rating and $45 target in Friday, December 11 report. The firm has “Buy” rating given on Monday, October 26 by Gabelli. Needham maintained Hologic, Inc. (NASDAQ:HOLX) on Friday, June 2 with “Buy” rating. As per Friday, September 23, the company rating was upgraded by Barclays Capital. On Thursday, July 30 the stock rating was maintained by Barclays Capital with “Underweight”.

Investors sentiment increased to 1.3 in 2016 Q4. Its up 0.06, from 1.24 in 2016Q3. It is positive, as 37 investors sold Hologic, Inc. shares while 146 reduced holdings. 70 funds opened positions while 168 raised stakes. 259.13 million shares or 2.17% more from 253.61 million shares in 2016Q3 were reported. Aviva Public Ltd Co has invested 0.04% in Hologic, Inc. (NASDAQ:HOLX). 815 are held by Kistler. Keybank National Association Oh holds 0.01% in Hologic, Inc. (NASDAQ:HOLX) or 22,980 shares. Blackrock has 0.05% invested in Hologic, Inc. (NASDAQ:HOLX). Mitsubishi Ufj Securities Holdings has 120 shares for 0.03% of their portfolio. California State Teachers Retirement Sys holds 0.05% in Hologic, Inc. (NASDAQ:HOLX) or 580,224 shares. 7,275 are owned by First Citizens Bankshares. Neuberger Berman Gru Ltd Llc holds 0% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 15,793 shares. Calamos Advsrs Lc stated it has 0.17% of its portfolio in Hologic, Inc. (NASDAQ:HOLX). Hsbc Holdings Public Limited stated it has 0.01% in Hologic, Inc. (NASDAQ:HOLX). Art Advisors Limited Liability Corp holds 0.28% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 115,500 shares. Brown Advisory has invested 0.02% in Hologic, Inc. (NASDAQ:HOLX). Westpac holds 0% or 168,619 shares in its portfolio. Meiji Yasuda Asset Management Ltd reported 12,377 shares or 0.06% of all its holdings. Curbstone Management Corp stated it has 6,478 shares.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The company has market cap of $13.02 billion. The Firm operates through four divisions: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. It has a 16.51 P/E ratio. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

About 214,215 shares traded. Impax Laboratories Inc (NASDAQ:IPXL) has declined 49.01% since June 20, 2016 and is downtrending. It has underperformed by 65.71% the S&P500.

Since May 12, 2017, it had 0 insider purchases, and 3 selling transactions for $43,046 activity. 700 shares were sold by NESTOR MICHAEL, worth $11,977 on Friday, May 12.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The company has market cap of $1.19 billion. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , in addition to the development and marketing of branded products. It currently has negative earnings. The Company’s divisions include Impax Generics and Impax Specialty Pharma.

Investors sentiment decreased to 1.18 in 2016 Q4. Its down 0.25, from 1.43 in 2016Q3. It fall, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. 36 funds opened positions while 61 raised stakes. 57.71 million shares or 5.44% less from 61.03 million shares in 2016Q3 were reported. Oxford Asset Management invested in 0.07% or 109,512 shares. Putnam Invs Ltd Company holds 0% or 39,336 shares in its portfolio. 2,360 were accumulated by Zurcher Kantonalbank (Zurich Cantonalbank). Profund Advsr Llc reported 25,714 shares or 0.02% of all its holdings. Landscape Capital Management Ltd Liability Company invested 0.07% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL). Strs Ohio has 0% invested in Impax Laboratories Inc (NASDAQ:IPXL) for 66,200 shares. Texas Permanent School Fund invested in 53,885 shares. Aqr Cap Mngmt Limited Liability stated it has 25,429 shares or 0% of all its holdings. Comerica Bancshares reported 78,608 shares. Goldman Sachs holds 345,777 shares or 0% of its portfolio. Price T Rowe Associate Md, Maryland-based fund reported 24,270 shares. Prelude Capital Mgmt Ltd Liability has 0.12% invested in Impax Laboratories Inc (NASDAQ:IPXL). Umb Bank N A Mo holds 0.01% or 11,600 shares in its portfolio. Riverhead Cap Management Limited Liability Corp reported 1,400 shares. Vanguard Gp owns 5.97 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: